Matthew J Ellis

29PUBLICATIONS
246CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Jul 15, 2026
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.

|Jan 16, 2026
Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer.

Bree M Lege, Khushali J Patel, Brendan Panici

|Aug 27, 2025
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors.

Ze-Yi Zheng, Anran Chen, Eric J Jaehnig

|Aug 08, 2025
Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer.

Nicholas J Neill, Shankha Satpathy, Karsten Krug

|Jun 23, 2025
Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole.

Judith-Anne W Chapman, Jane Bayani, Sandip SenGupta

|Jan 08, 2025
Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.

John F R Robertson, Zhimin Shao, Shinzaburo Noguchi

Pageof 5

Frequent Collaborators

10 joint publications

Meenakshi Anurag

8 joint publications

Jonathan T Lei

7 joint publications

Bing Zhang

6 joint publications

Beom-Jun Kim